My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Crinetics Pharmaceuticals, Inc. - Common Stock (NQ:CRNX)

46.67 -0.75 (-1.58%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Crinetics Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗

November 27, 2025

Here’s what a complete fund exit reveals about sentiment toward one of biotech’s endocrine drug developers.

Via The Motley Fool

Topics Regulatory Compliance

Why Crinetics Pharmaceuticals Stock Was Sliding on Friday ↗

November 07, 2025

The company is preparing a rollout of its recently FDA-approved acromegaly treatment.

Via The Motley Fool

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) Emerges as a Technical Breakout Candidate ↗

November 07, 2025

Crinetics Pharmaceuticals (CRNX) shows strong technical momentum and a high-quality consolidation setup, signaling a potential breakout opportunity for traders.

Via Chartmill

Crinetics Pharmaceuticals (NASDAQ:CRNX) Reports Q3 2025 Earnings Miss ↗

November 06, 2025

Crinetics Q3 2025 earnings miss estimates as it transitions to a commercial-stage company following the U.S. launch of its new drug, PALSONIFY.

Via Chartmill

Topics Earnings

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Retail Chatter Surges As Crinetics Wins FDA Nod For First Oral Acromegaly Drug — Traders Expect Big Price Move ↗

September 25, 2025

Via Stocktwits

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Earnings Scheduled For February 27, 2025 ↗

February 27, 2025

Via Benzinga

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

What Analysts Are Saying About Crinetics Pharmaceuticals Stock ↗

September 27, 2024

Via Benzinga

Fastenal Posts Downbeat Earnings, Joins Vince Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

October 13, 2025

Via Benzinga

Is Crinetics Pharmaceuticals Stock a Buy? ↗

September 28, 2025

The FDA just handed this clinical-stage biotech its golden ticket -- but at a $4.3 billion valuation, the market's already pricing in a fair amount of commercial success.

Via The Motley Fool

FDA Approves Crinetics Pharma's First Daily Pill For Rare Growth Disorder ↗

September 26, 2025

On Thursday, the U.S.

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

September 26, 2025

Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The market value of their outstanding shares is at $3.6 million.

Via Benzinga

Friday's session: gap up and gap down stocks ↗

September 26, 2025

Let's have a look at the gap up and gap down stocks in today's session.

Via Chartmill

Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On Friday ↗

September 26, 2025

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) rose sharply during Friday's session after the FDA...

Via Benzinga

Topics Stocks

Assessing Crinetics Pharmaceuticals: Insights From 4 Financial Analysts ↗

September 26, 2025

Throughout the last three months, 4 analysts have evaluated Crinetics Pharmaceuticals (NASDAQ: CRNX), offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments,...

Via Benzinga

Crinetics Pharma Surges After FDA OKs Its Treatment For A Form Of Gigantism ↗

September 26, 2025

The company's drug, Palsonify, treats acromegaly, a condition in which the pituitary gland makes too much growth hormone.

Via Investor's Business Daily

Topics Artificial Intelligence

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

September 26, 2025

Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The company's market cap stands at $4.5 million.

Via Benzinga

Tuesday's pre-market session: top gainers and losers ↗

August 19, 2025

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

August 19, 2025

Via Benzinga

Crinetics (CRNX) Q2 Revenue Jumps 150% ↗

August 07, 2025

Via The Motley Fool

Topics Intellectual Property

Crinetics Reports Durable Symptom, Hormone Control With Oral Drug In Acromegaly ↗

July 14, 2025

Crinetics shares PATHFNDR trial data showing oral Palsonify maintained hormone and symptom control in acromegaly patients over 84–96 weeks.

Via Benzinga

Crinetics Pharma’s Oral Drug Shows Lasting Relief For Acromegaly Patients In Latest Study; Retail Buzz Builds ↗

July 13, 2025

The company presented new data at ENDO 2025 showing that patients who switched from monthly injections to the daily pill maintained hormone control and saw fewer symptom flare-ups over nearly two...

Via Stocktwits

Topics Government

JP Morgan Survey: 90% Of Endocrinologists Are Aware Of Crinetics' Atumelnant Data ↗

March 26, 2025

JP Morgan's survey of endocrinologists finds strong awareness of Crinetics' atumelnant, with positive efficacy impressions. Analysts see long-term potential.

Via Benzinga

Crinetics Pharmaceuticals Analyst Sees Around 70% Upside For Stock, Cites More Investor Interest In Endocrinology ↗

March 25, 2025

Stifel initiates coverage on CRNX, a clinical-stage pharmaceutical company focused on endocrine diseases and tumors.

Via Benzinga

This Clearway Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

March 25, 2025

Via Benzinga

This Netflix Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday ↗

January 22, 2025

Via Benzinga

Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential ↗

December 16, 2024

Neurocrine's Crenessity receives FDA approval as a groundbreaking adjunctive treatment for classic CAH, offering a novel approach to hormone regulation.

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.